Literature DB >> 23486264

The prognostic value of ratio-based lymph node staging in resected non-small-cell lung cancer.

Chen Qiu1, Wei Dong, Benhua Su, Qi Liu, Jiajun Du.   

Abstract

INTRODUCTION: Assessment of lymph node status is a critical issue in the surgical management of non-small-cell lung cancer (NSCLC). We sought to determine the prognostic value of metastatic lymph node ratio (LNR) in patients with radical surgery for NSCLC.
METHODS: We abstracted data from 480 consecutive patients undergoing radical surgery for NSCLC between 2006 and 2008 in our institution. Kaplan-Meier estimated the survival function using the number of metastatic lymph node (MLN) and LNR as categorized variables. The prognostic value of age, sex, smoking status, location of tumor, histology, pathology T stage, pathology N stage, surgical procedure, chemotherapy, MLN, and LNR were assessed using a multivariate Cox proportional hazards model for overall survival (OS) and disease-free survival (DFS).
RESULTS: The median numbers of examined lymph nodes and MLNs were 15 and 5, respectively. Optimal cutpoints of the LNR were calculated as 0, 0 to 0.35, and greater than 0.35. Patients with higher LNR were associated with worse OS and DFS in the whole series, whereas there was no significant difference in the OS and DFS of those patients classified as pathology N2. A multivariate analysis showed that the LNR staging, smoking status, and chemotherapy were revealed to be independent prognostic factors.
CONCLUSIONS: LNR is an independent predictor of survival in patients with NSCLC undergoing radical resection; the prognostic significance is more valuable in patients classified as pathology N1.

Entities:  

Mesh:

Year:  2013        PMID: 23486264     DOI: 10.1097/JTO.0b013e3182829c16

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  19 in total

1.  A prognostic score system with lymph node ratio in stage IIIA-N2 NSCLC patients after surgery and adjuvant chemotherapy.

Authors:  Han Han; Yue Zhao; Zhendong Gao; Difan Zheng; Fangqiu Fu; Zitong Zhao; Ya Tang; Jiaqing Xiang; Yihua Sun; Hong Hu; Haiquan Chen
Journal:  J Cancer Res Clin Oncol       Date:  2019-06-07       Impact factor: 4.553

2.  The impact of positive nodal chain ratio on individualized multimodality therapy in non-small-cell lung cancer.

Authors:  Qinchen Cao; Baozhong Zhang; Lujun Zhao; Changli Wang; Liqun Gong; Jun Wang; Qingsong Pang; Kai Li; Weishuai Liu; Xue Li; Peng Wang; Ping Wang
Journal:  Tumour Biol       Date:  2015-01-27

3.  Risk factors associated with recurrence of surgically resected node-positive non-small cell lung cancer.

Authors:  Yoichi Ohtaki; Kimihiro Shimizu; Kyoichi Kaira; Toshiteru Nagashima; Kai Obayashi; Seshiru Nakazawa; Seiichi Kakegawa; Hitoshi Igai; Mitsuhiro Kamiyoshihara; Masahiko Nishiyama; Izumi Takeyoshi
Journal:  Surg Today       Date:  2016-01-19       Impact factor: 2.549

4.  Lack of supportive evidence for the use of immunohistochemical staining to identify occult regional lymph node metastases in primary lung cancer.

Authors:  Per Jönsson; Leif Johansson; Maria Planck; Hans Brunnström
Journal:  Virchows Arch       Date:  2014-02-27       Impact factor: 4.064

5.  Outcomes of locally advanced breast cancer patients with ≥ 10 positive axillary lymph nodes.

Authors:  Emre Koca; Taha Y Kuzan; Omer Dizdar; Taner Babacan; Ilyas Sahin; Erhan Ararat; Kadri Altundag
Journal:  Med Oncol       Date:  2013-06-01       Impact factor: 3.064

6.  Does anatomical location-based metastatic lymph node density affect prognosis in lung cancer patients?

Authors:  Yunus Aksoy; Necati Çıtak; Çiğdem Obuz; Muzaffer Metin; Adnan Sayar
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-10-04

7.  Spanish Lung Cancer Group SCAT trial: surgical audit to lymph node assessment based on IASLC recommendations.

Authors:  José Ramón Jarabo Sarceda; Sergio Bolufer Nadal; Roberto Mongil Poce; Pedro López de Castro; Ramón Moreno Balsalobre; Juan Carlos Peñalver Cuesta; Raul Embún Flor; Joaquín Pac Ferrer; Francisco Javier Algar Algar; Antonio Pablo Gámez García; Marcelo F Jiménez; Jesús Gabriel Sales-Badía; Eva Pereira; Bartomeu Massuti; Mariano Provencio; Florentino Hernando Trancho
Journal:  Transl Lung Cancer Res       Date:  2021-04

8.  The number of resected lymph nodes (nLNs) combined with tumor size as a prognostic factor in patients with pathologic N0 and Nx non-small cell lung cancer.

Authors:  Miaomiao Yang; Hongxin Cao; Xi Guo; Tiehong Zhang; Pingping Hu; Jiajun Du; Qi Liu
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

9.  Lymph node ratio is a prognostic factor for non-small cell lung cancer.

Authors:  Guangyuan Sun; Lei Xue; Mingdong Wang; Xuewei Zhao
Journal:  Oncotarget       Date:  2015-10-20

10.  Prognostic value of number of negative lymph node in patients with stage II and IIIa non-small cell lung cancer.

Authors:  Shengguang Wang; Bin Zhang; Chenguang Li; Chao Cui; Dongsheng Yue; Bowen Shi; Qiang Zhang; Zhenfa Zhang; Xi Zhang; Changli Wang
Journal:  Oncotarget       Date:  2017-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.